• TransCanna Holdings closed a recent round of private placement funding with aggregate gross proceeds of more than C$10 million
• TransCanna will use the funding to help grow its statewide vertically integrated cannabis production and distribution efforts in California’s robust marketplace
• Following an extensive search, the company has named a general manager for its 196,000-square-foot hub facility that will serve up to five satellites
• Pending acquisition projects are expected to expand TransCanna’s asset and brand options in the state

TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8), a company aiming to create and buy 15 premium brands in California, garnered aggregate gross proceeds of more than C$10 million during its just-closed round of private placement funding, which will be used to fund further equipment purchases for its vertically integrated cannabis facility in Modesto, California, as well as for additional acquisitions and other corporate purposes (http://ibn.fm/9rcrM).

TransCanna has been building a strong statewide operation in California – the largest marketplace in the global cannabis resurgence as adult lifestyle and wellness consumers drive a variety of plant-based sectors to robust financial activity. The company’s Modesto facility is a 196,000-square-foot cannabis-focused hub for its satellite operations that are expected to include integrated divisions for transportation and distribution, cultivation and nursery, lab extraction, and manufacturing and packaging. All of the activities within what is “arguably (the) largest vertically integrated cannabis focused facility in California” will be to satisfy the company’s own brands.

TransCanna believes that the highest probability of success in the cannabis marketplace centers on owning its own portfolio of premium brands, and it intends to provide all of the servicing for those brands (nursery, cultivation, manufacturing, extraction and distribution) through its self-contained eco-system. These efforts are being completed for scaling, with an aim of becoming one of the largest revenue-generating publicly traded cannabis companies in California.

The private placement round included an aggregate of more than two million units of shares and half-share purchase warrants in the company sold at C$5 per unit. The company has also engaged independent Toronto financial services organization Umbrella Capital Group Ltd. for market-making activities across a three-month term, according to TransCanna’s June 7 announcement.

The company’s plans include the development of 15 premium cannabis brands that will reach store shelves within the next two years. As part of the product-building strategy, TransCanna is working to acquire the asset packages for cannabis-infused fruit snacks producer Soldaze, high-end flower cultivator Lyted Farms and hemp-based CBD coconut oil maker Biovelle, and the new funding is expected to help advance those plans.

TransCanna recently named the general manager for its Modesto hub, which will serve up to five satellites throughout California, advancing the ramp-up of operations (http://ibn.fm/9x5iQ). Alan R. Applonie will be responsible for all activities relating to the manufacturing operations of the 196,000-square-foot facility, as well as other facilities and operations that TransCanna may acquire in Stanislaus County, according to the company.

“I’ve spent over six months interviewing for top-tier talent to oversee our operations and I firmly believe Alan is that person,” CEO Jim Pakulis stated in a news release. “Alan’s most recent position was for a multi-billion-dollar enterprise in which his division regularly produced greater than $300 million in annual revenues. We have no doubt he will add significant value to the TransCanna family of brands.”

Pakulis was featured in an eight-minute video tour of the site (http://ibn.fm/2mzVA) highlighting the company’s pride in its operations core on a 5.5-acre property parcel that the company may develop to about 400,000 square feet of new indoor growing space.

For more information, visit the company’s website at www.TransCanna.com

NOTE TO INVESTORS: The latest news and updates relating to TCAN are available in the company’s newsroom at http://ibn.fm/TCAN

• Green Hygienics signed a purchase order for the sale of hemp flower to the Tijuana-based firm over the course of five years
• Hemp flower from Green Hygienics will be used in the U.S. Tobacco de Mexico production lines; U.S. Tobacco de Mexico has over 20 brands of CBD hemp cigarettes
• The partnership is in line with the Green Hygienics growth strategy; the company generates revenue through innovative product development, as well as through strategic partnerships and acquisitions

Green Hygienics Holdings Inc. (OTCQB: GRYN) recently announced its entry into a multiyear purchase order for the sale of hemp to U.S. Tobacco de Mexico, an industry leader with over 20 different brands of CBD hemp cigarettes (http://ibn.fm/hvFMg). The lucrative five-year contract will require Green Hygienics to deliver $56.4 million worth of hemp flower to the Tijuana, Mexico-based firm for use in its production lines.

U.S. Tobacco de Mexico is a Tijuana-based tobacco and cigarette product importer. Its excellent management team and global positioning capabilities will provide various opportunities, making the partnership an exciting one, Green Hygienics Vice President of Business Development Matt Dole said in a news release.

Green Hygienics is working on strategic collaborations and market acquisitions. These corporate moves are expected to enable the company to position itself in the best possible way as the hemp market grows.

The U.S. hemp market alone is expected to grow nearly 10 times, to over $20 billion, by 2024 (http://ibn.fm/HX0WA). Currently, the U.S. hemp product market is estimated at $1.8 billion, but legislative changes such as the passing of the federal Farm Bill are expected to allow for much quicker growth in the future.

Globally, the CBD product market is expected to reach a volume of $16.32 billion by 2026, achieving a CAGR of 27.7 percent (http://ibn.fm/u67ln). Health care innovation, clinical research and a broader acceptance of hemp-based products are all expected to contribute to the expansion. The market is segmented into food-grade and therapeutic-grade products. The therapeutics products are anticipated to continue holding the largest market share, reaching $9.3 billion by 2026.

Green Hygienics Holdings is a full-scope, premium cannabis cultivation company that targets both high-end medical and recreational adult users. Company practices are based on over 25 years of experience in agricultural science and innovation.

The Green Hygienics growth strategy is based on the generation of revenue from premium grade cannabis products, the development and licensing of valuable IP, strategic acquisitions and the creation of global consumer brands in the niche.

Scientific innovation can be used to control the conditions and the factors that determine cultivation quality. Through its developments, Green Hygienics can monitor all aspects of cannabis cultivation to maximize yields and reduce the cost per gram in relationship to what competitors are capable of offering.

Green Hygienics Company is headquartered in Las Vegas, Nevada. It is also establishing operations in San Diego to target the $5 billion California market.

For more information, visit the company’s website at www.GreenHygienicsHoldings.com

NOTE TO INVESTORS: The latest news and updates relating to GRYN are available in the company’s newsroom at http://ibn.fm/GRYN

• Sproutly Canada’s executive team recently announced the company’s first commercial sale of cannabis flower to another licensed producer in Canada
• The sale marks a major milestone for Sproutly as the beginning of a new revenue stream that is in line with the company’s strategic expansion plans
• Sproutly also announced that it is awaiting the receipt of a sales license, allowing the company to sell more wholesale craft flower under its new brand, Caliber

Sproutly Canada Inc. (CSE: SPR) (OTCQB: SRUTF) (FRA: 38G) recently announced its first commercial sale of cannabis flower in Canada. Selling cannabis flower commercially to a recognized and licensed producer is a major milestone, Sproutly CEO Keith Dolo said in a company news release (http://ibn.fm/BqIrC). The shipment marks the beginning of a revenue stream, demonstrating the ability of the Sproutly team to bring the company’s strategy to reality, Dolo concluded.

Currently, Sproutly awaits its sales license from Health Canada. Once the license is received, followed by a thorough inspection, Sproutly may consider selling more wholesale craft flower to ensure consistent revenue generation. Following the receipt of its sales license from Health Canada, Sproutly plans to sell premium cannabis flower under its Caliber brand.

Caliber targets cannabis connoisseurs and high-end consumers. The high-quality manufacturing process and award-winning genetics typical for Sproutly are expected to enable the brand to deliver a superior cannabis experience.

Once the sales license is received, Sproutly plans to launch a Caliber brand campaign, soon to be followed by the distribution of the flower products. Both consumers and retailers will receive vital information about the product and its characteristics, as well as insights about the brand and what makes it different.

The Sproutly cannabis flower is produced by Toronto Herbal Remedies (THR), a fully owned company subsidiary. Its facility relies on modern production technologies and climate control to produce top-shelf premium cannabis flower. THR is in full production and harvesting weekly.

THR has a 16,600 square foot cultivation facility that is strategically located in the greater Toronto area. The facility received its Access to Cannabis for Medical Purposes Regulations (ACMPR) cultivation license from Health Canada in 2018. A processing license was also issued on April 1, 2019.

Sproutly Canada is on a mission to become the leading supplier of water-soluble cannabis bio-natural oils and solutions for cannabis beverage and edibles brands.

Leveraging its water-soluble bio-natural oils and solutions, Sproutly aims to deliver revolutionary brands to international markets through partnerships with well-established local consumer brands. This way, Sproutly will leverage an existing consumer base, expand brand loyalty and support distribution networks to deliver scientific breakthrough across the world.

Sproutly is mainly known for its groundbreaking, patented Aqueous Phytorecovery Process (APP). The technology replaces traditional water-compatible solutions with true and natural water solubility. This mechanism improves the body’s ability to utilize cannabinoids, making their effect almost immediate.

For more information, visit the company’s website at www.Sproutly.ca

NOTE TO INVESTORS: The latest news and updates relating to SRUTF are available in the company’s newsroom at http://ibn.fm/SRUTF

• Widely known as the “mother of all cannabinoids,” cannabigerol is believed to have multiple benefits and medical applications in areas such as autoimmune conditions, cancer, pain management, inflammation and more
• CBG oil’s market price in the U.S. is currently two to four times higher than the price of CBD oil
• As genetic advances lead to higher yields, CBG looks set to become a prominent part of the cannabinoid market
• Hemptown USA is working to ensure sustainable production of CBG and is positioned to produce about 40 percent of the North American supply of CBG in the near future

Cannabigerol (CBG) ranks among the cannabinoids that will potentially change the future of the cannabis product market. While CBD currently dominates the landscape, scientific advances and genetics could contribute to the rising prominence of CBG in the future.

Currently, the CBG content in most plants is very low – it remains less than one percent. However, genetics programs can boost that concentration and increase extraction yield. One of the companies at the forefront of CBG’s rise to prominence is Hemptown USA. With its 500-acre outdoor production facility in Oregon focused exclusively on CBG, and with access to over one million rare CBG seeds programmed to yield between 15 and 20 percent CBG, Hemptown is positioned to dominate the market.

The prominence of CBG is rising due to its multiple beneficial effects and a changing legislative landscape. What does the future hold for this currently rare cannabinoid? What have researchers discovered so far about it?

CBG: An Overview

CBG was discovered by Dr. Yechiel Gaoni and Professor Raphael Mechoulam in 1964. It is one of the cannabinoids exclusively produced by the cannabis plant. CBG is often called the mother of all cannabinoids, because it plays a crucial role in the synthesis of other cannabinoids.

CBG is non-psychotropic, which means that it doesn’t produce a high, like tetrahydrocannabinol (THC) does (http://ibn.fm/7Kc1o). In this sense, it is more similar to cannabidiol (CBD). THC and CBD, however, both start out as CBG in the plant. Cannabigerolic acid (CBGA) is the precursor to both of those, and, when specific enzymes in the plant break it down, it forms tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA) and cannabichromenic acid (CBCA).

In the plant, these acids are exposed to ultraviolet light and heat. This process contributes to the formation of THC, CBD and CBG (as well as other unique cannabinoids).

The nature through which these compounds are synthesized means that there will be a predominance of either THC or CBD in the plant. Scientists are currently working on the production of plants that produce more CBD and less THC. These genetic experiments have also been taken to the next level – attempting to boost the CBG yield of the plant.

The Numerous Potential Benefits of CBG

CBG is considered crucial for the cannabis industry, because clinical research so far suggests an array of important and beneficial effects.

Current literature suggests that CBG is a potent anti-inflammatory and anti-cancer agent (http://ibn.fm/VfGBR). While research has so far been limited due to the low concentrations of CBG in plants, genetic advances are giving the scientific community a chance to work with cannabigerol and test its complete range of diversified applications.

There’s some evidence that CBG is a good treatment option for anxiety and depression. In addition, it could be an effective natural option for addressing medical problems like glaucoma, inflammatory bowel disease, neurological conditions, bladder disorders and bacterial conditions.

CBG Production: Challenges to Overcome

Seed genetics play a crucial role in boosting CBG yield and making it readily available on the market. Companies like Hemptown are working hard to ensure the sustainable production of CBG. In fact, the company is projected to produce approximately 40 percent of the North American CBG supply in the near future.

The premium genetics of Hemptown seeds allow the company to grow plants to full maturity without compromising the CBG content. Usually, producers have to harvest very early in order to obtain CBG in the 1 to 2 percent range. As the plant grows, the quality of biomass improves and allows for maximized extraction efficiency. Once fully mature and ready for harvest, Hemptown’s Oregon crop is expected to yield a staggering 10 percent CBG.

Genetic work has already enabled scientists to produce the world’s first THC-free strains. These plants have high medicinal potential due to the optimal CBD and CBG concentrations (http://ibn.fm/tf2EA).

As CBG quantities in plants increase due to genetic advances, the compound will move out of the realm of the great unknown. In addition, the genetic modifications will be opening the door toward mass production due to optimized yields and more efficient processes. Steps in that direction have already been made, and it seems as though it’s only a matter of time before CBG products start dominating the market.

CBG Market Forecasts

CBG can increase the range of medicinal applications of other cannabinoids. It has been shown to have high pain relief potential (http://ibn.fm/6TUFF), while other research indicated benefits in the realm of autoimmune conditions (http://ibn.fm/pvKqP) and multiple sclerosis (http://ibn.fm/liJVd).

Companies like Hemptown are pioneers when it comes to the production of such innovative cannabinoids (http://ibn.fm/pcRvw). In 2019, the company acquired $5.5 million worth of Oregon CBD Seeds, including one million rare CBG seeds. In addition to Oregon, the company is also growing in Kentucky and Colorado, totaling just over 1,500 acres. Hemptown is projecting 2020 revenue from its 2019 harvest to exceed $200 million, and the company is planning to expand cultivation to 2,500 acres for the 2020 growing season.

Growing demand and the scarcity of CBG are determining factors for the current market dynamics. At the moment, the market price for CBG oil in the U.S. is two to four times the price of CBD oil. Pioneers such as Hemptown USA are already eyeing the multiple opportunities that CBG provides. As forecasts suggest that it’s likely that CBG will rival CBD and may even surpass its popularity in the years to come.

For more information, visit the company’s website at www.HemptownUSA.com

• TransCanna Holdings is working to establish 15 premium cannabis brands during the next two years in California, the world’s largest cannabis market
• TransCanna’s wholly owned TCM Distribution subsidiary is celebrating the recent acquisition of temporary manufacturing and distribution permits while continuing to seek state permits and permanent licenses
• The permits advance production efforts at TransCanna’s 10,000-square-foot satellite operation in Adelanto, California
• The City of Adelanto recently reduced taxes on cannabis transportation, lab services, cultivation enterprises and dispensaries
• TransCanna has signed an LOI to acquire Soldaze cannabis-infused fruit snacks, which has just added to its product line with a Spicy Mango entry
• TransCanna plans to centralize its statewide operations with a 196,000-square-foot self-contained facility in Modesto, California

TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) has received manufacturing and distribution permits for its adult-use cannabis production satellite in Southern California, marking its latest step forward in building an industry empire within the world’s largest marketplace for the lifestyle culture plant.

TransCanna’s 10,000-square-foot facility in Adelanto, California, will serve as a distribution satellite for goods transported to the Southern California region from the company’s 196,000-square-foot cannabis-focused hub in Modesto. The Adelanto facility will also serve as a site for the production, packaging and distribution of pre-rolled cannabis products and other products of similar nature, according to the company’s news release about the permits (http://ibn.fm/EXz2G).

The Adelanto City Council also provided encouragement to TransCanna’s operations, voting to reduce its local taxes from five percent to one percent on cannabis transportation and lab services, five percent to three percent on dispensaries, and $5 per month per square foot down to 42 cents per month per square foot on cannabis cultivation enterprises.

With the temporary permits in hand, the company’s wholly owned subsidiary, TCM Distribution Inc., is continuing to pursue permanent licenses for cannabis manufacturing and distribution, as well as the needed state permits.

“GoodFellas, one of the entities the Company is preparing to acquire, will be transferring all revenue generating distribution and manufacturing processes to Adelanto once the facility receives its Certificate of Occupancy from the city, and state distribution and manufacturing permits,” TransCanna CEO Jim Pakulis stated in a news release. “We anticipate this being completed by the end of June.”

GoodFellas is a full-service cannabis advertising and marketing agency with established consumer demand and ‘SKU velocity’ in its brand, Daily Cannabis Goods, which launched last August. The Daily brand has three quality, half-gram pre-rolled joints, and TransCanna plans to add three more SKUs once the acquisition is complete (http://ibn.fm/jBumg).

TransCanna’s empire-building strategy includes the establishment of 15 premium brands, with some of the brands expected to reach store shelves by the end of 2019. To further that end, the company has signed a non-binding letter of intent to acquire the branding asset package Soldaze, a cannabis-infused fruit snacks producer in California. Soldaze recently announced that its award-winning fruit snack brand has begun receiving pre-orders for its new Spicy Mango line, which it intends to begin shipping next month (http://ibn.fm/OtgMa). Soldaze president and co-founder Shawn Shevlin will lead TransCanna’s newly formed branding division in overseeing statewide sales, working from TransCanna’s Modesto hub as the acquisition agreement is completed (http://ibn.fm/xBG6p).

The Modesto hub facility is a three-story, multi-purpose building that’s expected to serve up to five satellites statewide as TransCanna grows. The self-contained cannabis operation is anticipated to include integrated divisions for transportation and distribution, cultivation and nursery, lab extraction, and manufacturing and packaging on a 5.5-acre property parcel that the company envisions as holding space for about 400,000 square feet of new indoor growing operations, Pakulis said during an eight-minute video tour of the large Modesto facility for The Green Scene Podcast (http://ibn.fm/tkKSM).

“We have so much growth ahead of us, it’s crazy,” Pakulis added.

For more information, visit the company’s website at www.TransCanna.com

NOTE TO INVESTORS: The latest news and updates relating to TCAN are available in the company’s newsroom at http://ibn.fm/TCAN

• VPRB’s CEO brings to the team 30 years of experience in sourcing, manufacturing, supply chain management, marketing, advertising and brand licensing
• The company’s COO played a pivotal role in launching VPR Brands’ cannabis-based product division
• VPR Brands has seen impressive quarterly results and is positioned as an up-and-coming player in the cannabis industry

VPR Brands LP (OTC: VPRB), an innovative technology holding company, has partnered with top international brands in an effort to rise to the top of the booming cannabis industry. The company’s assets include issued U.S. and Chinese patents for atomization-related products, including technology for medical marijuana vaporizers and electronic cigarette products and components.

The company currently boasts a strong portfolio of unique brands and is led by a team of seasoned industry professionals. CEO Kevin Frija has decades of experience in sourcing, manufacturing, supply chain management, marketing, advertising and brand licensing. In 2009, he became the president and chief executive officer of Vapor Corp., one of the first publicly traded electronic-cigarette companies. In 2016, Frija purchased the brands and wholesale business assets of Vapor Corp., which is now owned by VPR Brands. He currently leads VPR Brands as it creates inroads into the cannabis industry, a move that is bringing the company increasing sales and profit margins.

Chief Operating Officer Dan Hoff brings valuable experience working in the vaporizer and e-cigarette industry to VPR Brands. He has held various leadership positions at Vapor Corp., including overseeing financial management, accounting functions, supply chain management, product design and development, and key vendor relations. His role in the construction and expansion of VPR Brands’ cannabis-based product division has been instrumental in helping the company pivot toward cannabis products.

VPR Brands’ industry potential has been flying under the radar, but, owing to its experienced leadership and strong brand portfolio, the company has posted impressive quarterly results. First-quarter 2019 results revealed increased revenues, indicating a nearly 31 percent year-over-year increase to $1.3 million. Additionally, the company lowered its net loss from approximately $149,000 in 2018 to approximately $138,000 in 2019 (http://ibn.fm/rSa7Z). The company continues to maintain strong gross operating margins above 40 percent.

For more information, visit the company’s website at www.VPRBrands.com

NOTE TO INVESTORS: The latest news and updates relating to VPRB are available in the company’s newsroom at http://ibn.fm/VPRB

• Technology investment enterprise SinglePoint recently reported that its Direct Solar subsidiary recorded $1.7 million in solar installation contracts during a 30-day period, causing the company to ratchet up its revenue forecasts for the year
• The company expects to see about $803,769 in gross revenue and $361,541 in net profit from the contracts
• SinglePoint has also been focusing on the development of the hemp market, as hemp legalization in the United States has created a new pathway for agricultural profits
• SinglePoint’s ‘Strategics’ program, in cooperation with a national distribution partner that has access to several large retail chains, is providing a pathway to store shelves for startups

Innovative technology investment enterprise SinglePoint Inc. (OTCQB: SING) is celebrating the success of its bet on solar power broker Direct Solar, a company that uses the Lending Tree model of connecting loan seekers to a variety of loan providers nationwide to allow them to effectively shop for a service that most closely fits their needs.

SinglePoint acquired Direct Solar in April with expectations that sales would exceed $8.2 million during the four quarters following closure of the agreement (http://ibn.fm/dp85r), but Direct Solar “surpassed everyone’s expectations” by signing contracts to deploy $1.7 million in solar installations over a 30-day period ending in June, putting the company on course to profitability from a cashflow standpoint more quickly than anticipated.

“This acquisition puts SinglePoint on a huge trajectory path. This is not only a home run, but a grand slam in our eyes,” CEO Greg Lambrecht stated in a news release issued by the company on June 18 (http://ibn.fm/6LCu3). “These revenues and profits provide SinglePoint the ability to be in a profitable cash flow position and the opportunity to aggressively expand sales. For every dollar we are putting into marketing we are seeing a return of five.”

The company expects to see about $803,769 in gross revenue and $361,541 in net profit from the sales. Direct Solar is also preparing to add operations in Missouri and Florida to the six states where it has been brokering residential installations, a move that it expects to generate additional explosive revenue.

In addition to SinglePoint’s support for the clean energy interests of solar power customers, the company has been dedicating a significant measure of its focus to the hemp market, seeking a place in the burgeoning cannabidiol (CBD) supply chain that New York-based investment bank Cowen & Co. foresees as pulling in $15 billion by 2025 and researchers at BDS Analytics and Arcview Market Research predict could reach $20 billion by 2024 (http://ibn.fm/DoKsw).

According to SinglePoint, Direct Solar is now negotiating a line of credit for cannabis businesses and other small businesses that would allow Direct Solar to not only generate the sale but the ability to provide the financing for these business owners as well. The cannabis industry has long suffered from difficulty in completing transactions because of the banking industry’s general unwillingness to support businesses that can’t qualify for the federal government’s deposit insurance backing in light of the government’s prohibition of cannabis-related sales.

The federal government’s passage of the 2018 Farm Bill and its attendant approval of hemp cultivation as an agricultural product provided encouragement to farmers and ancillary businesses to support hemp as an alternative agricultural product – one that’s in steady demand from consumers as of late (http://ibn.fm/bx3kd).

SinglePoint’s ‘Strategics’ program is an effort to provide a pathway to market through a national distribution partner for qualifying companies with annual revenue above $2 million. The partner has access to chain outlets such as CVS, Walgreens, Rite-Aid, Dollar Tree and Kroger grocery stores.

“Until now, startup, established and fast-growing CBD product companies have faced tremendous challenges in growing their business beyond e-commerce and regional distribution due to the enormous capital and logistics involved,” SinglePoint President Wil Ralston added (http://ibn.fm/2fLLr).

For more information, visit the company’s website at www.SinglePoint.com

NOTE TO INVESTORS: The latest news and updates relating to SING are available in the company’s newsroom at http://ibn.fm/SING

• The Green Organic Dutchman is building a name for itself as it works on production build-up from 2,000 kilograms of cannabis to 200,000 kilograms
• The company has facilities in Canada and is making inroads in Europe and Mexico through pharmaceutical networks
• In the United States, TGOD is finding access to the $20 billion functional beverage industry segment

The advent of indoor cultivation that’s suitable for the cannabis industry has changed the commercial production capacity of marijuana and medical-grade cannabis suppliers. While the cannabis plant seeks the sun during the height of summer then flowers as the season ebbs, indoor cultivation technologies are allowing producers to grow the plant with a sharply increasing lifestyle appeal during virtually any season of the year.

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) is making a name for itself as it pursues an upward scaling strategy of building enclosed facilities for cannabis growth, anticipating that its purpose-built enterprise will progress from about 2,000 kilograms (4,400 pounds) of cannabis at its Ontario site this summer to 100 times that amount across all its sites when it reaches full capacity (http://ibn.fm/gLexA).

The Canada-based company, commonly known by ticker ‘TGOD’, is expanding its footprint to international markets, principally through wholly owned subsidiary HemPoland, which inked an agreement last month with Germany’s Mediakos UG haftungsbeschraenkt for the distribution of TGOD’s premium hemp-derived cannabidiol (CBD) brand, CannabiGold, to that country’s pharmacy market (http://ibn.fm/KHAmq). The company’s hemp oil extraction facility in Poland offers the potential of expansion throughout Europe and in other global markets with official PL-EKO-01 European Union certificates.

Through a joint venture with Mexico’s LLACA Grupo Empresarial, the company is reaching 4,500 pharmacies and 3,100 supermarkets throughout that country with its medicinal cannabis and hemp-derived wellness products.

The Green Organic Dutchman has also been operating two retail stores in Jamaica, where cannabis tourism goes hand-in-hand with sun-seeking travelers drawn to the island’s promise of idyllic rest and relaxation (http://ibn.fm/4Ba9j). Through a partnership with Symrise Inc., TGOD is also finding access to the $20 billion U.S. functional beverage category, including wellness, energy and sport recovery products (http://ibn.fm/HS5if).

The company aims to become the global leader in providing premium organic cannabis solutions for the betterment of people’s lives around the globe, building on applicable licenses in Canada and targeted partnerships in other countries.

“Through our certified organic product and process we know we are providing patients the best possible experience,” Chief Science Officer Dr. Rav Kumar stated in an interview with Proactive Investors (http://ibn.fm/AVbL4).

For more information, visit the company’s website at www.TGOD.ca

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://ibn.fm/TGODF

• Geyser Brands focuses on creating first-rate, cannabis-led health care products and brands
• The company leverages a proprietary, all-natural NanoFusion nano-emulsion delivery system
• Geyser is pursuing an acquisition of Solace Management Group Inc.

Geyser Brands Inc. (TSX.V: GYSR) is a foremost consumer health care company based in Vancouver, British Columbia. The company has an integrated production chain and formulation lab that develops unique products using hemp cannabidiol (CBD) for healthy lifestyle brands. Fundamentally, Geyser Brands builds and markets some of the leading cannabis products and brands in the world. Its proprietary nanotechnology formulations create products with superior bioavailability and efficacy. The company’s vision is to secure top positions in every market it enters (http://ibn.fm/CZOX6).

Geyser’s NanoFusion advanced delivery system rapidly and efficiently transports therapeutic agents directly to the bloodstream for maximum absorbency. NanoFusion provides premier bioavailability and solves problems with insolubility. It also provides a longer shelf life, stability of molecules and enhanced permeation that allows for deeper skin penetration. Moreover, NanoFusion​ improves the transport of active ingredients for site-specific targeting and delivers active ingredients across cell membranes for release within the cell. Its proprietary process creates the only all-natural nano-emulsion on the market.

Geyser Brands’ acquisition target is Solace Management Group Inc. Solace owns a varied set of brands and is a leader in cannabis product formulations and development. Its brands span the adult-recreational and medical cannabis markets, as well as pet-health and wellness and hemp markets. Solace’s brands include Apawthecary Pets, WildTails pet products, Apothecary Naturals and Apothecary Ink.

Solace’s cosmetics line is Apothecary Naturals, whose products include pain creams, lip balms and skin health products for men and women. Its pet line, Apawthecary Pets, supplies leading retail stores and vets in Canada with products for pain and anxiety. Its baked pet treats use a proprietary process for baking in the hemp without degrading the molecule, delivering dosage control and better quality.

Geyser Brands’ global market focus is hemp oil for worldwide brands, with CBD as a value-added ingredient where legal. The company has a portfolio of products in the pain relief, skin health, sleep, anxiety and pet health categories. The company’s goal is to leverage its knowledge and experience with cannabis, and its licensed production facility for manufacturing and distribution, to deliver cannabis health care products for the everyday consumer. Geyser’s tinctures, creams, cosmetics, functional foods and beverages, and natural health products are made with all-natural, biocompatible, biodegradable, nontoxic and noninflammatory materials.

Geyser Brands subsidiary Apothecary Botanicals operates a Health Canada-approved licensed production facility based just outside of Vancouver, British Columbia. It received its cultivation license in 2018 and its processing license in June 2019. It is currently completing laboratory modifications in anticipation of receiving an R&D license in the short term.

Through Solace Management Group, Geyser Brands recently announced the world’s first hemp-infused, freeze-dried pet food (http://ibn.fm/Sb0bl). Upon completion of the Solace acquisition, Geyser anticipates that WildTails’ products will use its proprietary NanoFusion technology to infuse hemp into proteins such as beef, chicken and fish. Negotiations for order-and-distribution contracts are expected to be announced in Q3 2019.

Geyser Brands presents an intriguing investment opportunity as it establishes new brands with hemp ingredients in a variety of markets. One of 150 Health Canada-approved cannabis LPs, the company has a strong footprint in Canada as it expands its existing markets. Geyser continues to focus on building an integrated production chain and formulation lab that will develop innovative products for its customers.

For more information, visit the company’s website at www.GeyserBrands.com

NOTE TO INVESTORS: The latest news and updates relating to GYSR are available in the company’s newsroom at http://ibn.fm/GYSR

• MustGrow’s patented technology derived from mustard seed utilizes the plant’s natural defense mechanisms
• The company’s first-generation granular technology may be fast-tracked for use in cannabis cultivation
• Its second-generation liquid formulation may be fast-tracked for use in cannabis and fruit & vegetable cultivation
• The economic impact of global crop losses due to parasitic nematodes is estimated at $100 billion per year

MustGrow Biologics Corp. is a private agricultural biotech company developing and commercializing specialized technology in the form of a natural biopesticide and bio-fertilizer that offers a much more palatable option for cannabis and fruit and vegetable growers that are unable to use synthetic pesticides and fertilizers. MustGrow’s novel, proprietary technology utilizes organic components refined from the mustard seed, leveraging the plant’s natural defense mechanism as a pre-plant/pot soil bio-fumigant/treatment to control soil-borne pests and diseases (http://ibn.fm/g9GQS).

The global fruit and vegetable market, along with the legal cannabis sector, is clearly ready for a proven product that certifies as an organic solution to an age-old problem for growers. Most plant-parasitic nematodes feed on the roots of plants, damaging the root system and reducing the plant’s ability to absorb water and nutrients. Damage from soil-borne parasitic nematodes causes about $100 billion in lost crops per year, with nematodes being responsible for up to 20 percent loss in certain fruit and vegetable crops (http://ibn.fm/pYufk).

MustGrow’s technologies provide nematode control that is equal and often superior to synthetic alternatives, resulting in elevated yields and increased returns for the grower. Continued use of modern synthetic crop protection products can create a resistance to these conventional products among pests. Advancements in integrated pest management solutions, along with an increase in organic farming, is expected to push the biopesticides market beyond $6 billion by 2023, ResearchandMarkets reports (http://ibn.fm/3v9FA).

MustGrow’s biopesticide has U.S. EPA (Environmental Protection Agency) and Canadian PMRA (Pest Management Regulatory Agency) labels as an approved organic solution. The company is also seeking approval to add cannabis as an accepted use, both in the U.S. and Canada. MustGrow’s research shows that when its product is used as a pre-plant/pot soil treatment, it may significantly help control many soil-borne diseases, pathogens and pests, including nematodes, fusarium, rhizoctonia and botrytis (gray mold) that affect the cannabis plant.

To date, the company has successfully completed more than 110 independent third-party field trials of its products. MustGrow is at the forefront of development of unique solutions to help fruit and vegetable growers and cannabis growers control pests and crop diseases.

For more information, visit the company’s website at www.MustGrow.ca